Sunday, June 7, 2026, is National Cancer Survivors Day — the annual observance that began on June 5, 1988, and is held on the first Sunday of June to honor the 18 million Americans living beyond a cancer diagnosis. It is a day that typically offers hope in abstract terms: statistics of five-year survival rates and remission milestones. This year, it arrives against the backdrop of what oncologists at the American Society of Clinical Oncology annual meeting in Chicago described on May 31 as a 'game-changing' development — a Phase 3 trial result that has redefined what survival means for patients with one of the deadliest cancers in medicine. For the oncology community in Dallas–Fort Worth, and for the patients at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center and Baylor Scott & White Health who will be asking their physicians about this drug in the coming weeks, the news from ASCO is not abstract. It is personally consequential.

The drug is daraxonrasib, a pan-RAS inhibitor developed by Revolution Medicines. In the RASolute 302 Phase 3 trial, it nearly doubled overall survival for patients with metastatic pancreatic cancer who had already received prior treatment — extending median overall survival from 6.7 months to 13.2 months. The risk of death was reduced by 60%. One-third of patients experienced at least a 20% reduction in tumor size. Dr. Brian Wolpin, the lead investigator, received a standing ovation from normally reserved researchers and physicians when he presented the results. That reaction — from a room of people who have spent careers navigating the grim statistics of pancreatic cancer — tells you more about the significance of these findings than any statistical summary can.

Read more

Why Pancreatic Cancer Has Been Called Undruggable — Until Now

Pancreatic adenocarcinoma carries one of the worst prognoses in oncology. It is the third-leading cause of cancer deaths in the United States, killing nearly 53,000 people each year. It is frequently asymptomatic until it has already spread widely — the pancreas sits deep behind other abdominal organs, and its symptoms (vague back pain, new-onset diabetes, weight loss) are nonspecific and easily attributed to other causes. When it is finally diagnosed, the average patient survives less than a year. For those whose cancer has spread to other organs and who have already failed first-line chemotherapy — the population in which daraxonrasib was tested — the options before this drug were limited to palliative chemotherapy regimens that typically provided a few additional weeks or months of life, often at the cost of significant toxicity.

The reason daraxonrasib is scientifically significant is the genetic mechanism it targets. The KRAS gene is mutated in approximately 92% of pancreatic cancers. For 40 years, KRAS was considered undruggable — the protein it produces lacks the binding pockets that small-molecule drugs need to inhibit it. Every pharmaceutical attempt to target KRAS directly failed until a new class of drugs called RAS inhibitors found a different approach: attacking the protein's interaction with its upstream activators rather than its active site. Dr. Wells Messersmith, who treated patients with the drug in clinical trials, reported: "I've treated patients with this drug, and it's actually fairly tolerable, so patients can preserve their quality of life." Unlike most chemotherapy drugs — cytotoxics that kill dividing cells more indiscriminately — patients on daraxonrasib do not experience hair loss or severely suppressed blood counts.

Dallas's Role in the Oncology Landscape — and the Cancer Burden in North Texas

The Dallas–Fort Worth metroplex is home to one of the most formidable oncology ecosystems in the United States. UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center is a National Cancer Institute-designated comprehensive cancer center and consistently ranks among the nation's best for cancer care. The institution has already demonstrated willingness to adopt cutting-edge technologies: earlier in 2026, UT Southwestern became the first institution in Texas to perform whole-liver chemotherapy delivery for metastatic uveal melanoma using the Hepzato Kit — a rare surgical-oncology procedure showing 80% one-year overall survival. DFW-area patients with pancreatic cancer harboring RAS mutations who have failed first-line treatment should discuss daraxonrasib clinical trial eligibility with their oncologist immediately. Revolution Medicines is expected to file for FDA approval based on the Phase 3 data in the second half of 2026.

The Bigger Picture: Cancer Survival Rates at a Historic High

Daraxonrasib arrives amid the broader good news documented in the American Cancer Society's Cancer Statistics 2026 report: the five-year relative survival rate for all cancers combined has reached a historic high of 70% — up from 49% in the mid-1970s. Since 1991, the U.S. cancer death rate has declined by 34%, with approximately 4.8 million deaths prevented. Prostate cancer death rates are down 53% since 1993. Breast cancer mortality has fallen 44% since 1989. These achievements are the downstream product of decades of federal investment in basic cancer research through the NIH and NCI — investment whose continuity is, the ACS explicitly warns, now threatened by proposed federal cuts to cancer research budgets.

For the survivors attending National Cancer Survivors Day events at Baylor Scott & White Health's facilities across DFW, at Medical City Healthcare campuses, and at UT Southwestern's Simmons Cancer Center on Sunday, June 7, the day carries a specific meaning in 2026: not only are they alive — which in itself represents the triumph of the past decades of cancer research — but they are living in a year when even pancreatic cancer, medicine's longest-standing death sentence, may be about to yield to a drug that works. That is the best kind of National Cancer Survivors Day news that DFW oncologists have ever had to share.